

NCT02689089 Raw comparison:

Summary:
CHIA has 18 criteria while your personal folder has 22 criteria
Total found criteria: 18/18
Total not Found: 0/18
Total Extra: 4
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Males or non-pregnant non-nursing females between  │ Males or non-pregnant non-nursing females between  │
│ the ages of 2-65 years                             │ the ages of 2-65 years                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ LTBI diagnosis as per Canadian TB Standards using  │ LTBI diagnosis as per Canadian TB Standards using  │
│ either the Tuberculin Skin Test (TST) or the       │ either the Tuberculin Skin Test (TST) or the       │
│ Interferon Gamma Release Assay (IGRA)              │ Interferon Gamma Release Assay (IGRA)              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Children 2-5 years with negative TSTs who have     │ Children 2-5 years with negative TSTs who have     │
│ been in close contact with a case of active TB     │ been in close contact with a case of active TB     │
│ disease recently                                   │ disease recently                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able and willing to provide fully informed consent │ Able and willing to provide fully informed consent │
│ or parent/guardian able to provide consent         │ or parent/guardian able to provide consent         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Suspected or confirmed active TB disease           │ Suspected or confirmed active TB disease           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known allergies to any of the study medications by │ Known allergies to any of the study medications by │
│ participant self-report                            │ participant self-report                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ have a positive pregnancy test at screening or     │ have a positive pregnancy test at screening or     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ are not willing to use a reliable method of        │ are not willing to use a reliable method of        │
│ barrier contraception during the study or          │ barrier contraception during the study or          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ are breastfeeding                                  │ are breastfeeding                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ hormonal contraception                             │ hormonal contraception                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HIV infected participants who are on anti-         │ HIV infected participants who are on anti-         │
│ retroviral drugs                                   │ retroviral drugs                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ other drugs that interact with 3HP (see Table 1)   │ other drugs that interact with 3HP (see Table 1)   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known contact with an INH or rifampin resistant    │ Known contact with an INH or rifampin resistant    │
│ case                                               │ case                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Weight < 10 kg                                     │ Weight \< 10 kg                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of possible liver damage defined by an    │ Evidence of possible liver damage defined by an    │
│ aspartate transaminase (AST) level that is more    │ aspartate transaminase (AST) level that is more    │
│ than 3x the upper limit of normal in an            │ than 3x the upper limit of normal in an            │
│ asymptomatic patient                               │ asymptomatic patient                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Porphyria reported by patient                      │ Porphyria reported by patient                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inability to adhere to protocol                    │ Inability to adhere to protocol                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients may be excluded from the study for other  │ Patients may be excluded from the study for other  │
│ reasons at the investigator's discretion with      │ reasons at the investigator's discretion with      │
│ detailed documentation                             │ detailed documentation                             │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒══════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════╡
│ Female participants of childbearing potential who                                    │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ Unable/unwilling to substitute medications with drug interactions with 3HP including │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ Must have maximum age of 65 Years                                                    │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 2 Years                                                     │
╘══════════════════════════════════════════════════════════════════════════════════════╛